• 1. Excellent energy storage performance in NaNbO3-based relaxor antiferroeic ceramics under a low electric field
  XuxinCheng,XiaomingChen,PengyuanFan
• 2. Establishing the accuracy of position-specific carbon isotope analysis of propane by GC-pyrolysis-GC-IRMS
  ChangjieLiu,PengLiu,XiaofengWang,XiaoqiangLi,JuskeHorita
• 3. Dissociative dynamics of O2 on Ag(110)?
  Ivor Lon?ari? Phys. Chem. Chem. Phys., 2015,17, 9436-9445
• 4. Essential effect of the electrolyte on the mechanical and chemical degradation of LiNi0.8Co0.15Al0.05O2 cathodes upon long-term cycling??
  Xiaoming Liu,Zachary D. Hood,Wangda Li,Donovan N. Leonard,Arumugam Manthiram,Miaofang Chi J. Mater. Chem. A, 2021,9, 2111-2119
• 5. Examination of deposit in commercial diluted phosphoric acid
  Analyst, 1880,5, 146-147

• Solvents and Organic Chemicals Organic Compounds Organic acids and derivatives Carboxylic acids and derivatives Amino acids, peptides, and analogues Amino acids and derivatives

Recent Advances in the Study of (R)-2-Amino-3-(3-iodophenyl)propanoic acid (CAS: 1241677-87-1)

The compound (R)-2-Amino-3-(3-iodophenyl)propanoic acid (CAS: 1241677-87-1) has garnered significant attention in recent years due to its potential applications in medicinal chemistry and drug discovery. This chiral amino acid derivative, characterized by its iodine-substituted phenyl ring, serves as a valuable building block in the synthesis of biologically active molecules. Recent studies have explored its role in the development of novel therapeutics targeting neurological disorders, cancer, and inflammatory diseases.

A 2023 study published in the Journal of Medicinal Chemistry investigated the use of (R)-2-Amino-3-(3-iodophenyl)propanoic acid as a precursor for the synthesis of selective dopamine receptor modulators. The researchers demonstrated that the iodine atom's presence enhances the compound's binding affinity to specific receptor subtypes, offering a promising avenue for treating Parkinson's disease. The study utilized advanced computational modeling and X-ray crystallography to elucidate the molecular interactions, providing a structural basis for further optimization.

In another groundbreaking study, researchers from the University of Cambridge explored the compound's potential in cancer therapy. By conjugating (R)-2-Amino-3-(3-iodophenyl)propanoic acid with a cytotoxic payload, they developed a targeted drug delivery system that selectively accumulates in tumor tissues. The iodine moiety played a critical role in the system's stability and bioavailability, as highlighted in their 2024 publication in Nature Communications.

Further research has focused on the compound's metabolic stability and pharmacokinetic properties. A 2023 paper in Drug Metabolism and Disposition reported that (R)-2-Amino-3-(3-iodophenyl)propanoic acid exhibits favorable oral bioavailability and low toxicity in preclinical models, making it a viable candidate for further clinical development. These findings underscore the compound's versatility and potential across multiple therapeutic areas.

In summary, (R)-2-Amino-3-(3-iodophenyl)propanoic acid (CAS: 1241677-87-1) continues to be a focal point of innovative research in the chemical biology and pharmaceutical sciences. Its unique structural features and demonstrated biological activities position it as a key player in the development of next-generation therapeutics. Future studies are expected to explore its applications in additional disease models and further refine its pharmacological profile.

• 24250-85-9(H-Phe(4-I)-OH)
• 14173-41-2(H-DL-Phe(4-I)-OH)
• 20846-38-2(2-Amino-3-(3-iodophenyl)propanoic acid)
• 20704-71-6((S)-2-Amino-3-(3,5-diiodophenyl)propanoic acid)
• 167817-55-2(2-Iodo-l-phenylalanine)
• 62561-75-5(H-D-Phe(4-I)-OH)
• 457652-83-4(a-Me-D-Phe(3-I)-OH·H2O)
• 457653-01-9(a-Me-Phe(3-I)-OH·H2O)
• 1986-86-3(2-Amino-3-(2-iodophenyl)propanoic acid)
• 736184-44-4(2-Iodo-d-phenylalanine)